Skip to main content
. 2023 Jul 27;62:102117. doi: 10.1016/j.eclinm.2023.102117

Table 1.

Demographic and clinical characteristics patients.

Variable Placebo (N = 130) Bosentan (N = 129) Total (N = 259)
Age, Year 45.99 ± 13.20 45.73 ± 11.29 45.86 ± 12.26
Male 73 (56.2) 79 (61.2) 152 (58.7)
Risk factors
 Age ≥ 50 years 55 (52.4) 50 (47.6) 105 (40.5)
 BMI ≥ 25 67 (51.5) 63 (48.5) 130 (50.2)
 Diabetes Mellitus 80 (61.5) 82 (63.5) 162 (62.5)
 Hypertension 50 (38.5) 39 (30.2) 89 (34.4)
 Tobacco or Nicotine User 19 (14.6) 24 (18.6) 43 (16.6)
 Serious heart condition 5 (3.8) 7 (5.4) 12 (4.6)
 COPD 12 (9.2) 11 (8.5) 23 (8.9)
Number of risk factors
 1 28 (21.5) 37 (28.7) 65 (25.1)
 2 58 (44.6) 49 (38) 107 (41.3)
 3 37 (28.5) 39 (30.2) 76 (29.3)
 4 7 (5.4) 4 (3.1) 11 (4.2)
Days from illness onset to admission 3 (2–3) 3 (2–3) 3 (2–3)

BMI, Body Mass Index; COPD, Chronic obstructive pulmonary disease.

Data are reported as X2 test (n, %), T test (mean, SD) or Median (Q1–Q3).